Posts

Posted on

Texxon Holding Limited Announces Annual General Meeting

SHANGHAI, China, April 23, 2026 (GLOBE NEWSWIRE) — Texxon Holding Limited (Nasdaq: NPT) (the “Company” or “Texxon”), a leading provider of supply chain management services in the plastics and chemical industries in East China, today announced that it will hold its 2026 Annual General Meeting of Shareholders (the “2026 Annual Meeting”) at 9:00 A.M. on May 22, 2026, Beijing time (9:00 P.M. on May 21, 2026, U.S. Eastern time). The 2026 Annual Meeting will be held via a virtual meeting, and shareholders will have the option to attend and participate via live webcast at the following link: www.virtualsharehokfermeeting.com/NPT2026.

The Company has established the close of business on April 23, 2026, Eastern time (the “Record Date”), as the record date for determining shareholders entitled to notice of, and to vote at, the 2026 Annual Meeting and any adjournments or postponements thereof. At the 2026 Annual Meeting, shareholders will be asked to consider the following proposals:

     (1)   to re-appoint each of Hui Xu, Bo Ren, Lei Qin, Kang Zhou and Wei Li as directors of the Company to serve on the Company’s board of directors (the “Board”) until the next annual general meeting of shareholders or until their office is otherwise vacated or they are removed;

     (2)   to approve and adopt the Texxon Holding Limited 2026 Equity Incentive Plan;

     (3)   to ratify the appointment of ZH CPA, LLC as the independent auditor of the Company for the fiscal year ending June 30, 2026;

    (4)   to approve a sub-division of the ordinary shares, at a ratio of not less than 1-to-1 and not more than 1-to-5, with the final ratio to be determined by the Board in its sole discretion at any time during the one year anniversary of the 2026 Annual Meeting after approval by the shareholders (the “Share Split”);

     (5)   to amend and restate the current memorandum and articles of association of the Company to reflect the Share Split, if implemented by the Board;

     (6)   to approve a consolidation of the ordinary shares, at a ratio of not less than 1-to-1 and not more than 20-to-1, with the final ratio to be determined by the Board in its sole discretion at any time the one-year anniversary of the 2026 Annual Meeting after approval by the shareholders (the “Share Consolidation”); and

     (7)   to amend and restate the memorandum and articles of association of the Company to reflect the Share Consolidation, if implemented by the Board.

The Company expects to file with the Securities Exchange Commission the notice and proxy statement of the 2026 Annual Meeting on or around April 28, 2026. Copies of such notice and proxy statement, once available, will be accessible on the Company’s corporate investor relations website at https://ir.npt-cn.com/.

About Texxon Holding Limited

Texxon Holding Limited is a leading provider of supply chain management services in the plastics and chemical industries in East China. Through its technology-enabled platform, the Company provides a full spectrum of services to Chinese SME customers, including procurement, shipping and logistics, payments and fulfillment services. It aspires to build the largest one-stop plastic and chemical raw material supply chain management platform in China, to streamline the complex and labor-intensive raw material procurement process and enhance convenience, cost-effectiveness, and efficiency for customers. Texxon has built a highly scalable distributed software architecture for continuous improvement, and an effective User Experience Design (UED) process to improve the customer experience. In addition, with over a decade of experience, the Company has amassed substantial transaction data, including supplier and customer information, price trends, category-specific price indexes and market demand volume, to analyze price trends and market demands and make informed decisions. For more information, please visit the Company’s website: https://ir.npt-cn.com/.


Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, but not limited to, the statements regarding the expected timeline, commissioning, and production of the Henan Polystyrene Factory. These forward-looking statements involve known and unknown risks and uncertainties related to market condition and other factors discussed in the “Risk Factors” section of the Company Annual Report on Form 20-F for the fiscal year ended June 30, 2025 filed with the U.S. Securities And Exchange Commission and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions in this announcement. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s latest Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission.

For more information, please contact:

Texxon Holding Limited

Investor Relations Department
Email: [email protected]

Ascent Investor Relations LLC

Tina Xiao
Phone: +1-646-932-7242
Email: [email protected]



Posted on

NIQ and INTAGE HD Partner to Expand Retail Measurement Across Japan and Global Markets

NIQ and INTAGE HD Partner to Expand Retail Measurement Across Japan and Global Markets

TOKYO–(BUSINESS WIRE)–
NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, and INTAGE HOLDINGS Inc. (hereafter “INTAGE HD”), a leading market research company in Japan, today announced a mutual sales partnership to expand access to retail measurement insights between Japan and global markets.

Through the collaboration, NIQ and INTAGE HD bring together complementary strengths— INTAGE HD’s deep local retail store panel data and insights into the Japanese domestic market, and NIQ’s global and regional retail store panel data and insights into various international markets—to enable better comparison and understanding of market performance and trends across countries and regions.

This collaboration enhances both companies’ ability to support clients with more consistent and comparable insights, helping clients unlock growth opportunities across markets.

The collaboration enables global clients to access INTAGE HD’s nationwide retail store panel data in Japan (SRI+ and SRI+EC) to support market entry and expansion. NIQ’s network will enable smoother access to data and insights on the Japanese market. At the same time, clients in Japan will gain access to NIQ’s global Retail Measurement Services (RMS), covering more than 100 countries and regions, supporting international growth.

“Clients today are increasingly looking for a more complete and connected understanding of consumer buying behavior across markets,” said Chang Park, Managing Director of NIQ’s Northeast Asia Cluster. “Our collaboration with INTAGE HD strengthens our ability to deliver The Full View™—bringing together local depth and global scale to help clients unlock new opportunities and drive growth.”

This collaboration addresses a key challenge for clients: limited comparability between Japan and other markets by connecting local and global data more seamlessly.

Whether expanding into Japan or growing in international markets, clients will benefit from a more unified view of performance.

“Japan is a highly complex and unique market, and a deep understanding of the local market and a global perspective are both essential to realizing business growth,” said Yoshiya Nishi, CEO of INTAGE HOLDINGS Inc. “Through this collaboration, we will combine the strengths of both companies to provide more consistent and actionable insights in the Japanese and global markets, strongly supporting our clients’ decision-making and growth.”

This collaboration reflects a shared commitment by NIQ and INTAGE HD to help clients navigate increasingly interconnected markets with greater clarity and confidence.

About INTAGE HOLDINGS Inc.

Founded in 1960, the INTAGE Group is a leading marketing research company, ranked No.1 in Asia*. Guided by our vision of “Know today, Power tomorrow,” we leverage massive amounts of data obtained from Japan’s largest consumer panel (SCI) and retail panel (SRI+) to support decision-making across a wide range of industries through data and technology. In recent years, we have increased our support for digital transformation (DX) through data utilization, and accelerated the expansion of our global operations, primarily in Asia, contributing to the creation of a sustainable society.

* Based on ESOMAR’s Global Top-50 Insights Companies 2025 (in terms of the Group’s consolidated net sales).

About INTAGE Group

(TSE Prime Market stock code: 4326)

Since its founding in 1960, the INTAGE Group has collected, processed, and analyzed a wide range of data, adding unique insights to provide its clients with valuable information and support their decision-making processes. As a partner to our clients, we work closely with them to address their questions, combining consumer insights with technology to guide them toward their next strategic move.

ABOUT NIQ

NielsenIQ (NYSE: NIQ) is a leading consumer intelligence company, delivering the most complete and trusted understanding of consumer buying behavior and revealing new pathways to growth. By combining an unmatched global data footprint and granular consumer and retail measurement with decades of AI modelling expertise, NIQ builds decision systems that help companies turn complex data into confident action.

With operations in more than 90 countries, NIQ covers approximately 82% of the world’s population and more than $7.4 trillion in global consumer spend. Through cloud-based platforms, advanced analytics and AI-driven insights, NIQ delivers The Full View™—helping brands and retailers understand what consumers buy, why they buy it, and what to do next.

For more information, please visit www.niq.com.

NIQ-GENERAL

Media contacts:

NIQ – [email protected]

KEYWORDS: Japan Asia Pacific

INDUSTRY KEYWORDS: Other Consumer Technology Other Retail Business Professional Services Software Data Analytics Consumer Retail

MEDIA:

Logo
Logo
Posted on

X-energy Announces Pricing of Upsized Initial Public Offering

X-energy Announces Pricing of Upsized Initial Public Offering

ROCKVILLE, Md.–(BUSINESS WIRE)–
X-energy, Inc. (“X-energy”), a leader in advanced nuclear reactor and fuel technology, today announced the pricing of its upsized initial public offering (“IPO”) of 44,254,659 shares of its Class A common stock at a public offering price of $23.00 per share. In connection with the offering, X-energy has granted the underwriters a 30-day option to purchase up to an additional 6,638,198 shares of Class A common stock.

The shares are expected to begin trading on the Nasdaq Global Select Market (“Nasdaq”) on April 24, 2026, under the ticker symbol “XE.” The offering is expected to close on April 27, 2026, subject to customary closing conditions.

J.P. Morgan, Morgan Stanley, Jefferies, and Moelis & Company acted as the lead joint book-running managers for the offering.

A registration statement related to the shares being sold in this offering was declared effective by the U.S. Securities and Exchange Commission on April 23, 2026 (the “Registration Statement”). This offering is being made only by means of a prospectus, copies of which may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected] and [email protected]; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388 or by email at [email protected]; or Moelis & Company LLC, Attention: Melissa Mariaschin, Managing Director and Head of Distribution, Capital Markets, 399 Park Avenue, 5th Floor, New York, NY 10022, or by email at [email protected].

Important Information

The Registration Statement may be obtained free of charge at the SEC’s website at www.sec.gov under “X-Energy, Inc.” This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About X-energy

X-Energy, Inc. is a leading developer of advanced small modular nuclear reactors and fuel technology for clean energy generation that is redefining the nuclear energy industry through its development of safer and more efficient advanced small modular nuclear reactors and proprietary fuel to deliver clean, safe, reliable energy that meet the demands of the modern economy. X-energy’s simplified, modular, and intrinsically safe SMR design expands applications and markets for deployment of nuclear technology and drives enhanced safety, lower cost and faster construction timelines when compared with other SMRs and conventional nuclear.

Cautionary Statement Concerning Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. The words “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “seek,” “foreseeable,” the negative version of these words, or similar terms and phrases are intended to identify forward-looking statements. These forward-looking statements include any statements regarding the commencement of trading of the Class A shares on Nasdaq and the expected closing date of X-energy’s initial public offering. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described in the Registration Statement.

Any forward-looking statement speaks only as of the date on which it is made, and, except as required by law, X-energy does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for X-energy to predict all such factors. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements in the Registration Statement. The risk factors and other factors noted in the Registration Statement could cause its actual results to differ materially from those contained in any forward-looking statement.

Robert McEntyre, Corporate Communications

[email protected]

+1 240.673.6565

Patricia Gil, Investor Relations

[email protected]

+1 301.558.3040

KEYWORDS: Maryland United States North America

INDUSTRY KEYWORDS: Nuclear Energy Utilities

MEDIA:

Logo
Logo
Posted on

Resolutions Adopted at the Annual General Ordinary Shareholders’ Meeting for Grupo Aeroportuario Del Pacifico on April 22, 2026

GUADALAJARA, Mexico, April 23, 2026 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces the following resolutions adopted at the Annual General Ordinary Shareholders’ Meetings held yesterday, with a quorum of 84.01%:

I.   In compliance with Article 28 section IV of the Securities Market Law, the following were approved:
  a)  The Chief Executive Officer’s report regarding the results of operations for the fiscal year ended December 31, 2025, in accordance with Article 44, Section XI of the Mexican Securities Market Law and Article 172 of the Mexican General Corporations Law, together with the external auditor’s report, with respect to the Company on an unconsolidated basis in accordance with Mexican Financial Reporting Standards (“MFRS”), as well as with respect to the Company and its subsidiaries on a consolidated basis in accordance with International Financial Reporting Standards (“IFRS”), based on the latest statements of financial position for fiscal year 2025 under both standards, as well as the Sustainability Report for fiscal year 2025.
  b) Board of directors’ opinion on the Chief Executive Officer’s report.
  c) Board of directors’ report in accordance with Article 172, clause b, of the Mexican General Corporations Law, regarding the Company’s main accounting policies and criteria, as well as the information used to prepare the Company’s financial statements.
  d) Report on transactions and activities undertaken by the Company’s Board of Directors during the fiscal year ended December 31, 2025, pursuant to the Mexican Securities Market Law.
     
  e) Report on the activities carried out by the Audit and Corporate Practices Committee in accordance with Article 43 of the Securities Market Law. Ratification of the actions taken by the different committees and release from further obligations in the fulfillment of their duties.
  f) Report on compliance with the Company’s tax obligations for the fiscal year from January 1 to December 31, 2024. Instruction to the Company’s officers to comply with the corresponding tax obligations for the fiscal year from January 1 to December 31, 2025, in accordance with Article 26 section III of the Mexican Fiscal Code.
     
II.   Ratification of the actions of our Board of Directors and the Company’s management and release from further obligations in the fulfillment of their duties.
     
III.   Approval of the Company’s non-consolidated financial statements for the period from January 1 to December 31, 2025, prepared under MFRS for purposes of the legal reserve, profit allocation, calculation of tax effects of dividend payments and capital reductions, if applicable. Also, the consolidated financial statements of the Company and its subsidiaries prepared under IFRS for publication in the securities markets, regarding the operations carried out during the fiscal year from January 1 to December 31, 2025, and approval of the external auditor’s opinion with respect to both financial statements.
     
IV.    Approval that the net income obtained by the Company during the fiscal year ended December 31, 2025, reported in the Company’s non-consolidated financial statements presented to the meeting under Item III above and audited under MFRS, amounting to $9,343,142,610.00 (NINE BILLION THREE HUNDRED FORTY-THREE MILLION ONE HUNDRED FORTY-TWO THOUSAND SIX HUNDRED TEN PESOS 00/100 M.N.), be fully transferred to the account of retained earnings pending allocation, without setting aside any amount for the legal reserve fund, since the current fund represents 20% of the historical capital stock required by Article 20 of the Mexican General Corporations Law.
     
V.   Approval that from the retained earnings pending allocation account, which amounts to $20,379,864,675.00 (TWENTY BILLION THREE HUNDRED SEVENTY-NINE MILLION EIGHT HUNDRED SIXTY-FOUR THOUSAND SIX HUNDRED SEVENTY-FIVE PESOS 00/100 M.N.), a dividend of $20.80 (TWENTY PESOS 80/100 M.N.) per share be declared, payable to the holders of each of the shares outstanding on the payment date, excluding the shares repurchased by the Company in accordance with Article 56 of the Securities Market Law. The remaining balance, after the dividend payment, will remain in the retained earnings pending allocation account. The dividend will be payable in one or more installments within the 12 (twelve) months following April 22, 2026.
     
VI.   Approval of the cancellation of any amount outstanding under the share repurchase program approved at the Annual General Ordinary Shareholders’ Meeting held on April 24, 2025, in the amount of $2,500,000,000.00 (TWO BILLION FIVE HUNDRED MILLION PESOS 00/100 M.N.). Also, approval of the maximum amount to be allocated for the repurchase of the Company’s own shares or securities representing such shares for an amount of $2,500,000,000.00 (TWO BILLION FIVE HUNDRED MILLION PESOS 00/100 M.N.), for the period of 12 (twelve) months following April 22, 2026, in accordance with Article 56 section IV of the Securities Market Law.
     
VII.   Acknowledge of the designation of the four principal members of the Board of Directors and their respective alternates appointed by the Series “BB” shareholders as follows:
     
    Proprietary members                                     Alternate members

Laura Díez Barroso Azcárraga                        Claudia Laviada Díez Barroso
Emilio Rotondo Inclán                                      Roberto Ángel Ramírez García
Juan Gallardo Thurlow                                     Mónica Sánchez Navarro Rivera Torres
María de los Reyes Escrig Teigeiro                 Carlos Alberto Rohm Campos
VIII.    It is registered that there was no designation of person(s) that will serve as member(s) of the Company’s Board of Directors, by any holder or group of holders of Series B shares that owns, individually or collectively, 10% or more of the Company’s capital stock. 
     
IX.   Ratification and designation of Carlos Cárdenas Guzmán, Ángel Losada Moreno, Joaquín Vargas Guajardo, Juan Diez-Canedo Ruíz, Luis Téllez Kuenzler, Jerónimo Marcos Gerard Rivero and Alejandra Yazmín Soto Ayech, as members of the Board of Directors, designated by the Series “B” shareholders. 

As of this date, the Board of Directors will be comprised as follows: 

Proprietary members                                    Alternate members
Laura Díez Barroso Azcárraga                       Claudia Laviada Díez Barroso
Emilio Rotondo Inclán                                     Roberto Ángel Ramírez García
Juan Gallardo Thurlow                                    Mónica Sánchez Navarro Rivera Torres
María de los Reyes Escrig Teigeiro                Carlos Alberto Rohm Campos
Carlos Cárdenas Guzmán                              Not applicable
Ángel Losada Moreno                                     Not applicable
Joaquín Vargas Guajardo                               Not applicable
Juan Diez-Canedo Ruíz                                  Not applicable
Luis Téllez Kuenzler                                        Not applicable
Jerónimo Marcos Gerard Rivero                     Not applicable
Alejandra Yazmín Soto Ayech                         Not applicable 
     
X.   Ratification of Mrs. Laura Díez Barros Azcárraga as Chairwoman of Company’s the Board of Directors, in accordance with Article Sixteenth of the Company’s bylaws.
     
XI.   Approval of the compensation paid to members of the Company’s Board of Directors during fiscal year 2025 and the compensation to be paid to the Company’s Board of Directors for the 2026 fiscal year proposed by the Compensation and Nominations Committee.
     
XII.   Ratification of Mr. Luis Téllez Kuenzler, as member of our Board of Directors designated by the Series “B” shareholders to serve as member of the Nominations and Compensation Committee, in accordance with Article Twenty-Eighth of the Company’s bylaws.
     
XIII.   Ratification of Mr. Carlos Cárdenas Guzmán as President of the Audit and Corporate Practices Committee.
     
XIV.   It was informed the Report in accordance with Article Twenty-Ninth of the Company’s bylaws regarding transactions involving the acquisition of goods or services, contracting of works, or sale of assets equal to or greater than US$3,000,000 (THREE MILLION U.S. DOLLARS) or its equivalent in Mexican pesos or other currencies, or transactions carried out by relevant shareholders, if any.
     
     
XV.   Approval of special delegates that can appear before a Notary Public to formalize the resolutions adopted at this meeting.



Company Description

Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (GAP) operates 12 airports throughout Mexico’s Pacific region, including the major cities of Guadalajara and Tijuana, the four tourist destinations of Puerto Vallarta, Los Cabos, La Paz and Manzanillo, and six other mid-sized cities: Hermosillo, Guanajuato, Morelia, Aguascalientes, Mexicali, and Los Mochis. In February 2006, GAP’s shares were listed on the New York Stock Exchange under the ticker symbol “PAC” and on the Mexican Stock Exchange under the ticker symbol “GAP”. In April 2015, GAP acquired 100% of Desarrollo de Concessioner Aeroportuarias, S.L., which owns a majority stake in MBJ Airports Limited, a company operating Sangster International Airport in Montego Bay, Jamaica. In October 2018, GAP entered into a concession agreement for the Norman Manley International Airport operation in Kingston, Jamaica, and took control of the operation in October 2019.

This press release may contain forward-looking statements. These statements are statements that are not historical facts and are based on management’s current view and estimates of future economic circumstances, industry conditions, company performance, and financial results. The words “anticipates”, “believes”, “estimates”, “expects”, “plans” and similar expressions, as they relate to the company, are intended to identify forward-looking statements. Statements regarding the declaration or payment of dividends, the implementation of principal operating and financing strategies and capital expenditure plans, the direction of future operations, and the factors or trends affecting financial condition, liquidity, or results of operations are examples of forward-looking statements. Such statements reflect the current views of management and are subject to a number of risks and uncertainties. There is no guarantee that the expected events, trends, or results will occur. The statements are based on many assumptions and factors, including general economic and market conditions, industry conditions, and operating factors. Any changes in such assumptions or factors could cause actual results to differ materially from current expectations.

In accordance with Section 806 of the Sarbanes-Oxley Act of 2002 and Article 42 of the “Ley del Mercado de Valores”, GAP has implemented a “whistleblower” program, which allows complainants to anonymously and confidentially report suspected activities that involve criminal conduct or violations. The telephone number in Mexico, facilitated by a third party responsible for collecting these complaints, is 800 04 ETICA (38422) or WhatsApp +52 55 6538 5504. The website is www.lineadedenunciagap.com or by email at [email protected]. GAP’s Audit Committee will be notified of all complaints for immediate investigation.

Alejandra Soto Investor Relations and Social Responsibility Officer

Gisela Murillo, Investor Relations

 [email protected]

[email protected]
+52 33 3880 1100 ext. 20294



Posted on

Borealis Foods Inc. Receives Expected Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K for Fiscal 2025

TORONTO, April 23, 2026 (GLOBE NEWSWIRE) — Borealis Foods Inc. (Nasdaq: BRLS) (the “Company”) today announced that on April 17, 2026, the Company received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company’s failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “2025 Form 10-K”) with the Securities and Exchange Commission (the “SEC”). The Notice has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Capital Market.

In accordance with Nasdaq’s listing rules, the Company has until June 16, 2026 to submit a plan of compliance to Nasdaq addressing how the Company intends to regain compliance with the Listing Rule. If Nasdaq accepts the Company’s plan, Nasdaq may grant the Company up to 180 calendar days from the filing’s due date, or until October 12, 2026, to regain compliance. The Company intends to file the 2025 Form 10-K as soon as practicable but anticipates no later than May 2026, which the Company believes will cure the deficiency and regain compliance with the Listing Rule.

About Borealis Foods Inc.

Borealis Foods Inc. is a food science company focused on developing and commercializing innovative, nutritious, and affordable food products. The Company’s common stock is listed on the Nasdaq Capital Market under the symbol “BRLS.” www.borealisfoods.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, statements regarding the Company’s anticipated timing for filing the 2025 Form 10-K and the Company’s ability to regain compliance with Nasdaq’s listing rules. Forward-looking statements are generally identified by words such as “anticipates,” “believes,” “expects,” “intends,” “plans,” “will” and similar expressions. These statements are based on the Company’s current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements, including risks related to the completion of the Company’s financial statements and related audit, the Company’s ability to file the 2025 Form 10-K within the anticipated timeframe, the Company’s ability to regain and maintain compliance with Nasdaq’s continued listing requirements, and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission. The Company’s filings with the SEC are available at www.sec.gov. Investors should not place undue reliance on the Company’s forward-looking statements. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.

Contact:
Henry Wong
CMO
Borealis Foods
1540 Cornwall Rd
Oakville, ON
(905) 278-2200



Posted on

Provident Financial Holdings Announces Quarterly Cash Dividend

RIVERSIDE, Calif., April 23, 2026 (GLOBE NEWSWIRE) — Provident Financial Holdings, Inc. (“Company”), NASDAQ GS: PROV, the holding company for Provident Savings Bank, F.S.B., today announced that the Company’s Board of Directors declared a quarterly cash dividend of $0.14 per share. Shareholders of the Company’s common stock at the close of business on May 14, 2026 will be entitled to receive the cash dividend. The cash dividend will be payable on June 4, 2026.

Safe-Harbor Statement

Certain matters in this News Release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may relate to, among others, expectations of the business environment in which the Company operates, projections of future performance, perceived opportunities in the market, potential future credit experience, and statements regarding the Company’s mission and vision. These forward-looking statements are based upon current management expectations, and may, therefore, involve risks and uncertainties. The Company’s actual results, performance, or achievements may differ materially from those suggested, expressed, or implied by forward-looking statements as a result of a wide range of factors including, but not limited to, the general business environment, interest rates, the California real estate market, competitive conditions between banks and non-bank financial services providers, regulatory changes, and other risks detailed in the Company’s reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended June 30, 2025.

     
Contact: Donavon P. Ternes Peter C. Fan
  President and Senior Vice President and
  Chief Executive Officer Chief Financial Officer
  (951) 686-6060  

                                                                 



Posted on

Mobileye Releases First Quarter 2026 Results, Updates Full-Year Outlook, and Announces a $250 Million Share Repurchase Program

Mobileye Releases First Quarter 2026 Results, Updates Full-Year Outlook, and Announces a $250 Million Share Repurchase Program

  • Revenue of $558 million in the first quarter increased 27% year over year compared to Q1 2025. We are raising the midpoint of our full-year 2026 revenue guidance by 2% to reflect better-than-expected demand in the first quarter.

  • Diluted EPS (GAAP) was $(4.68) and Adjusted Diluted EPS (Non-GAAP) was $0.12 in the first quarter.

  • GAAP Operating Loss was impacted by a non-cash goodwill impairment of $3,788 million related to the goodwill asset on Mobileye’s balance sheet resulting from Intel’s acquisition of Mobileye in 2017.

  • Generated $75 million of operating cash flow in the first quarter of 2026. The acquisition of Mentee Robotics Ltd. (“Mentee Robotics”) closed in early February, resulting in a reduction in our cash balance of $591 million, net of cash acquired.

  • Announced an up to $250 million share repurchase authorization, intended to partially offset dilution associated with stock-based compensation and shares issued as part of the Mentee Robotics acquisition in the first quarter.

JERUSALEM–(BUSINESS WIRE)–
Mobileye Global Inc. (Nasdaq: MBLY) (“Mobileye”) today released its financial results for the three months ended March 28, 2026.

“First quarter results reflected a stronger than expected start to 2026, and continued favorable demand trends enable us to modestly increase our 2026 outlook. We also secured an important design win with Mahindra which adds a third Surround ADAS customer and a second customer for our next-generation SuperVision product,” said Mobileye President and CEO Professor Amnon Shashua. “In parallel, we achieved significant milestones related to our robotaxi technology stack and our EyeQ6H-based Supervision L2++ and Chauffer L3 programs with VW group. Continued execution across these programs is key both to converting our advanced product pipeline into future revenue growth and to winning additional customers.”

First Quarter 2026 Business Highlights

  • The Mobileye Drive / MOIA / VW ID.Buzz robotaxi ecosystem progressed significantly during the first quarter. VW and MOIA announced the kick off of pre-series production at VW’s Hanover plant in March. MOIA America and Beep announced Orlando as their initial test deployment location, and began on-road validation testing with Uber in Los Angeles. There are now more than 100 ID.Buzz AVs powered by Drive testing on public roads in six cities (LA, Austin, Orlando, Munich, Berlin, and Hamburg), with Oslo coming soon. We believe Mobileye Drive technology has meaningful scaling advantages over the competition and look forward to continued strong execution over the course of 2026.

  • For the first time, EyeQ6 High-based SuperVision is operating in the US inside pre-production vehicles. An extended 2,000+ kilometer drive, on an unplanned route, achieved targeted mean-time-between-failure goals in urban, suburban, and highway road types, as well as severe weather, and outperformed other systems used as benchmarks.

  • We announced SuperVision and Surround ADAS design wins with Mahindra. We continue to see significant potential for growth in the India market for both ADAS and AV, and are encouraged that Mahindra believes that advanced mobility products based on Mobileye solutions can serve as competitive differentiators in the mid-trim and premium vehicle segments.

First Quarter 2026 Financial Summary and Key Highlights (Unaudited)

GAAP

U.S. dollars in millions

 

 

Q1 2026

 

 

Q1 2025

 

% Y/Y

Revenue

 

$

558

 

 

$

438

 

 

27

%

Gross Profit

 

$

275

 

 

$

207

 

 

33

%

Gross Margin

 

 

49

%

 

 

47

%

 

+202bps

Operating Income (Loss)

 

$

(3,896

)

 

$

(117

)

 

*NM

Operating Margin

 

 

(698

)%

 

 

(27

)%

 

*NM

Net Income (Loss)

 

$

(3,818

)

 

$

(102

)

 

*NM

EPS – Basic

 

$

(4.68

)

 

$

(0.13

)

 

*NM

EPS – Diluted

 

$

(4.68

)

 

$

(0.13

)

 

*NM

 

 

 

 

 

 

 

*Not Meaningful

Non-GAAP

U.S. dollars in millions

 

 

Q1 2026

 

 

Q1 2025

 

% Y/Y

Revenue

 

$

558

 

 

$

438

 

 

27

%

Adjusted Gross Profit

 

$

370

 

 

$

301

 

 

23

%

Adjusted Gross Margin

 

 

66

%

 

 

69

%

 

(241)bps

Adjusted Operating Income (Loss)

 

$

95

 

 

$

59

 

 

61

%

Adjusted Operating Margin

 

 

17

%

 

 

13

%

 

+360bps

Adjusted Net Income (Loss)

 

$

96

 

 

$

63

 

 

52

%

Adjusted EPS – Basic

 

$

0.12

 

 

$

0.08

 

 

51

%

Adjusted EPS – Diluted

 

$

0.12

 

 

$

0.08

 

 

51

%
  • Revenue increased 27% compared to the first quarter of 2025, primarily due to a 28% ramp up in EyeQ SoC volumes attributable to higher EyeQ demand. A portion of this growth was related to the normalization of safety stock levels at customers, after some draw down that took place in the fourth quarter of 2025.

  • Gross Margin increased by nearly 2 percentage points in the first quarter of 2026 as compared to the prior year period. The increase was primarily due to similar levels of amortization of intangible assets on a significantly higher revenue base, partially offset by a higher EyeQ-related cost per unit given the different mix of EyeQ products sold.

  • Adjusted Gross Margin decreased by nearly 2 percentage points in the first quarter of 2026 as compared to the prior year period. This was mainly due to a higher EyeQ-related cost per unit given the different mix of EyeQ products sold.

  • An additional item that is part of this quarter’s reconciliation of GAAP to Non-GAAP earnings is a non-cash impairment loss related to the Goodwill asset on our balance sheet. This asset originally resulted from the Intel acquisition of Mobileye in 2017 and was pushed down to our balance sheet in connection with the IPO in 2022 and separation from Intel. During the quarter, due to a decline in our market capitalization since the most recent assessment date, as well as increased uncertainty in the macroeconomic and geopolitical environment, an interim impairment test was triggered. The resulting analysis led to an approximately $3,788 million write-down of goodwill. For more information, see our Quarterly Report on Form 10-Q for the period ended March 28, 2026.

  • Operating Margin decreased meaningfully in the first quarter of 2026 as compared to the prior year period. This was primarily due to goodwill impairment loss of $3,788 million recognized in the first quarter of 2026.

  • Adjusted Operating Margin increased to 17% in the first quarter of 2026 as compared to 13% in the prior year period. This is related to significantly higher year-over-year revenue which resulted in lower operating expenses as a percentage of revenue.

  • Operating cash flow for the three months ended March 28, 2026 was $75 million, including transaction costs and cash paid for accelerated options as part of the Mentee Robotics acquisition. Cash used in purchases of property and equipment was $30 million for that same period.

Financial Guidance for the 2026 Fiscal Year

The following information reflects Mobileye’s expectations for Revenue, Operating Loss and Adjusted Operating Income results for the full year 2026. Our updated guidance reflects a 2% increase in expected revenue, at the midpoint, due to higher-than-expected EyeQ unit shipments in the first quarter. Our outlook for Adjusted Operating Income is increased by 8% at the midpoint, reflecting operating leverage on the higher revenue outlook. We are providing a 2026 outlook for Operating Loss now that the Mentee Robotics acquisition has closed. At the time of our Q4 2025 earnings release, prior to closing of the Mentee Robotics acquisition, our outlook for stock-based compensation and amortization of intangible assets was not able to be estimated with precision.

We believe Adjusted Operating Income (a non-GAAP metric) is an appropriate metric as it excludes significant non-cash expenses including: 1) Amortization charges related to intangible assets consisting of developed technology, customer relationships and brands, and developed IP as a result of Intel’s acquisition of Mobileye in 2017 and the acquisition of Mentee Robotics in 2026; 2) Share-based compensation expense; 3) Goodwill impairment; and 4) acquisition-related expenses. These statements represent forward-looking information and may not represent a financial outlook, and actual results may vary. Please see the risks and assumptions referred to in the Forward-Looking Statements section of this release.

 

 

Full Year 2026

U.S. dollars in millions

 

Low

 

High

Revenue

 

$

1,935

 

 

$

2,015

 

Operating Loss

 

$

(4,331

)

 

$

(4,281

)

Amortization of acquired intangible assets

 

$

346

 

 

$

346

 

Share-based compensation expense

 

$

376

 

 

$

376

 

Goodwill impairment

 

$

3,788

 

 

$

3,788

 

Acquisition related expenses

 

$

6

 

 

$

6

 

Adjusted Operating Income

 

$

185

 

 

$

235

 

Earnings Conference Call Webcast Information

Mobileye will host a conference call today, April 23, 2026, at 8:00 am ET (3:00pm IT) to review its results and provide a general business update. The conference call will be accessible live via a webcast on Mobileye’s investor relations site, which can be found at ir.mobileye.com, and a replay of the webcast will be made available shortly after the event’s conclusion.

Non-GAAP Financial Measures

This press release contains Adjusted Gross Profit and Margin, Adjusted Operating Income and Margin, Adjusted Net Income and Adjusted EPS, which are financial measures not presented in accordance with GAAP. We define Adjusted Gross Profit as gross profit presented in accordance with GAAP, excluding amortization of acquisition related intangibles and share-based compensation expense. Adjusted Gross Margin is calculated as Adjusted Gross Profit divided by total revenue. We define Adjusted Operating Income (Loss) as operating loss presented in accordance with GAAP, adjusted to exclude amortization of acquisition related intangibles, share-based compensation expenses, impairment of goodwill and acquisition-related expenses. Operating margin is calculated as Operating Income (Loss) divided by total revenue, and Adjusted Operating Margin is calculated as Adjusted Operating Income divided by total revenue. We define Adjusted Net Income as net loss presented in accordance with GAAP, adjusted to exclude amortization of acquisition related intangibles, share-based compensation expense, impairment of goodwill, acquisition-related expenses and the related income tax effects. Income tax effects have been calculated using the applicable statutory tax rate for each adjustment taking into consideration the associated valuation allowance impacts. The adjustment for income tax effects consists primarily of the deferred tax impact of the amortization of acquired intangible assets. Adjusted Basic EPS is calculated by dividing Adjusted Net Income for the period by the weighted-average number of common shares outstanding during the period. Adjusted Diluted EPS is calculated by dividing Adjusted Net Income (Loss) by the weighted-average number of common shares outstanding during the period, while giving effect to all potentially dilutive common shares to the extent they are dilutive.

We use such non-GAAP financial measures to make strategic decisions, establish business plans and forecasts, identify trends affecting our business, and evaluate performance. For example, we use these non-GAAP financial measures to assess our pricing and sourcing strategy, in the preparation of our annual operating budget, and as a measure of our operating performance. We believe that these non-GAAP financial measures, when taken collectively, may be helpful to investors because they allow for greater transparency into what measures our management uses in operating our business and measuring our performance, and enable comparison of financial trends and results between periods where items may vary independent of business performance. The non-GAAP financial measures are presented for supplemental informational purposes only, should not be considered a substitute for financial information presented in accordance with GAAP, and may be different from similarly titled non-GAAP measures used by other companies. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure presented in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures.

About Mobileye Global Inc.

Mobileye (Nasdaq: MBLY) leads the mobility revolution with our autonomous driving and driver-assistance technologies, harnessing world-renowned expertise in artificial intelligence, computer vision and integrated software and hardware. Since our founding in 1999, Mobileye has enabled the global adoption of advanced driver-assistance systems that save countless lives and reduce crashes, while pioneering groundbreaking technologies such as REM™ crowdsourced road intelligence, Imaging Radar and Compound AI. These technologies drive the ADAS and AV fields towards the future of mobility – enabling self-driving vehicles and mobility solutions at scale, and powering industry-leading ADAS products. Through 2025, more than 230 million vehicles worldwide have been built with Mobileye’s EyeQ technology inside. In 2026, Mobileye acquired Mentee Robotics to pursue the future of physical AI and humanoid robots. Since 2022, Mobileye has been listed independently from Intel (Nasdaq: INTC), which retains majority ownership. For more information, visit https://www.mobileye.com.

“Mobileye,” the Mobileye logo and Mobileye product names are registered trademarks of Mobileye Global. All other marks are the property of their respective owners.

Forward-Looking Statements

Mobileye’s business outlook, guidance and other statements in this release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operations, including Mobileye’s 2026 full-year guidance, projected future revenue and descriptions of our business plan and strategies. These statements often include words such as “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast,” or the negative of these terms, and other similar expressions, although not all forward-looking statements contain these words. We base these forward-looking statements or projections, including Mobileye’s full-year guidance, on our current expectations, plans and assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances and at such time. You should understand that these statements are not guarantees of performance or results. The forward-looking statements and projections are subject to and involve risks, uncertainties and assumptions and you should not place undue reliance on these forward-looking statements or projections. Although we believe that these forward-looking statements and projections are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results or results of operations and could cause actual results to differ materially from those expressed in the forward-looking statements and projections.

Important factors that may materially affect such forward-looking statements and projections include the following: further deterioration of macroeconomic conditions due to ongoing global economic and political uncertainty; future business, strategic and financial performance, goals and measures; our anticipated growth prospects and trends in markets and industries relevant to our business; business and investment plans; expectations about our ability to maintain or enhance our leadership position in the markets in which we participate; future consumer demand and behavior, including expectations about excess inventory utilization by customers; our ability to effectively compete in the markets in which we operate; increased competition from emerging chip manufacturers and OEMs; future products and technology, and the expected availability and benefits of such products and technology; the humanoid robotics industry and its accompanying technology may not develop as expected; development of regulatory frameworks for current and future technology; changes in regulation and trade policy, including increased tariffs, in regions in which we operate, including the U.S., Europe and China; projected cost and pricing trends; future production capacity and product supply; potential future benefits and competitive advantages associated with our technologies and architecture and the data we have accumulated; the future purchase, use and availability of products, components and services supplied by third parties, including third-party IP and manufacturing services; uncertain events or assumptions, including statements relating to our estimated vehicle production and market opportunity, potential production volumes associated with design wins and other characterizations of future events or circumstances; adverse conditions in Israel, including as a result of war and geopolitical conflict, which may affect our operations and may limit our ability to produce and sell our solutions; any disruption in our operations by the obligations of our personnel to perform military service as a result of current or future military actions involving Israel; availability, uses, sufficiency and cost of capital and capital resources, including expected returns to stockholders such as dividends, and the expected timing of future dividends; tax- and accounting-related expectations; sustained low levels of our share price and market capitalization as well as other factors may require further testing of our Mobileye reporting unit, which may result in an impairment of goodwill; the ability to meet our social and environmental goals and projections.

The estimates included herein are based on projections of future production volumes that were provided by our current and prospective OEMs at the time of sourcing the design wins for the models related to those design wins. For the purpose of these estimates, we estimated sales prices based on our management’s estimates for the applicable product bundles and periods. Achieving design wins is not a guarantee of revenue, and our sales may not correlate with the achievement of additional design wins. Moreover, our pricing estimates are made at the time of a request for quotation by an OEM (in the case of estimates related to contracted customers), so that worsening market or other conditions between the time of a request for quotation and an order for our solutions may require us to sell our solutions for a lower price than we initial expected. These estimates may deviate from actual production volumes and sale prices (which may be higher or lower than the estimates) and the amounts included for prospective but uncontracted production volumes may never be achieved. Accordingly, these estimations are subject to and involve risks, uncertainties and assumptions and you should not place undue reliance on these forward-looking statements or projections.

Detailed information regarding these and other factors that could affect Mobileye’s business and results is included in Mobileye’s SEC filings, including the company’s Annual Report on Form 10-K for the year ended December 27, 2025, particularly in the section entitled “Item 1A. Risk Factors”. Copies of these filings may be obtained by visiting our Investor Relations website at ir.mobileye.com or the SEC’s website at www.sec.gov.

First Quarter 2026 Financial Results

Mobileye Global Inc.

Condensed Consolidated Statements of Operations (unaudited)

 

 

Three Months Ended

U.S. dollars in millions, except share and per share amounts

 

March 28, 2026

 

March 29, 2025

Revenue

 

$

558

 

 

$

438

 

Cost of revenue

 

 

283

 

 

 

231

 

Gross profit

 

 

275

 

 

 

207

 

Research and development, net

 

 

323

 

 

 

275

 

Sales and marketing

 

 

29

 

 

 

31

 

General and administrative

 

 

31

 

 

 

18

 

Goodwill impairment

 

 

3,788

 

 

 

—

 

Total operating expenses

 

 

4,171

 

 

 

324

 

Operating income (loss)

 

 

(3,896

)

 

 

(117

)

Financial income (expense), net

 

 

14

 

 

 

18

 

Income (loss) before income taxes

 

 

(3,882

)

 

 

(99

)

Benefit (provision) for income taxes

 

 

64

 

 

 

(3

)

Net income (loss)

 

$

(3,818

)

 

$

(102

)

 

 

 

 

 

Earnings (loss) per share attributed to Class A and Class B stockholders:

 

 

 

 

Basic and diluted

 

$

(4.68

)

 

$

(0.13

)

Weighted-average number of shares used in computation of earnings (loss) per share attributed to Class A and Class B stockholders (in millions):

 

 

 

 

Basic and diluted

 

 

817

 

 

 

812

 

Mobileye Global Inc.

Condensed Consolidated Balance sheets (unaudited)

U.S. dollars in millions

 

March 28, 2026

 

December 27, 2025

Assets

 

 

 

 

Current assets:

 

 

 

 

Cash and cash equivalents

 

$

1,211

 

$

1,836

Marketable securities and deposits

 

 

133

 

 

55

Trade accounts receivable, net

 

 

226

 

 

131

Inventories

 

 

303

 

 

327

Other current assets

 

 

120

 

 

129

Total current assets

 

 

1,993

 

 

2,478

Non-current assets:

 

 

 

 

Property and equipment, net

 

 

468

 

 

473

Intangible assets, net

 

 

1,181

 

 

1,166

Goodwill

 

 

4,911

 

 

8,200

Other long-term assets

 

 

182

 

 

175

Total non-current assets

 

 

6,742

 

 

10,014

TOTAL ASSETS

 

$

8,735

 

$

12,492

Liabilities and Equity

 

 

 

 

Current liabilities:

 

 

 

 

Accounts payable and accrued expenses

 

$

228

 

$

228

Employee related accrued expenses

 

 

137

 

 

141

Related party payable

 

 

3

 

 

4

Other current liabilities

 

 

51

 

 

33

Total current liabilities

 

 

419

 

 

406

Non-current liabilities:

 

 

 

 

Long-term employee benefits

 

 

78

 

 

78

Deferred tax liabilities

 

 

5

 

 

60

Other long-term liabilities

 

 

69

 

 

67

Total non-current liabilities

 

 

152

 

 

205

TOTAL LIABILITIES

 

$

571

 

$

611

TOTAL EQUITY

 

 

8,164

 

 

11,881

TOTAL LIABILITIES AND EQUITY

 

$

8,735

 

$

12,492

Mobileye Global Inc.

Condensed Consolidated Cash Flows (unaudited)

 

 

Three Months Ended

U.S. dollars in millions

 

March 28, 2026

 

March 29, 2025

 

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

 

Net income (loss)

 

$

(3,818

)

 

$

(102

)

 

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

 

 

 

 

 

Depreciation of property and equipment

 

 

20

 

 

 

18

 

 

Share-based compensation

 

 

80

 

 

 

65

 

 

Amortization of intangible assets

 

 

113

 

 

 

111

 

 

Goodwill impairment

 

 

3,788

 

 

 

—

 

 

Exchange rate differences on cash and cash equivalents

 

 

(2

)

 

 

(2

)

 

Deferred income taxes

 

 

(72

)

 

 

(6

)

 

Changes in operating assets and liabilities:

 

 

 

 

 

Decrease (increase) in trade accounts receivable

 

 

(95

)

 

 

(5

)

 

Decrease (increase) in other current assets

 

 

8

 

 

 

15

 

 

Decrease (increase) in inventories

 

 

24

 

 

 

51

 

 

Decrease (increase) in other long-term assets

 

 

—

 

 

 

3

 

 

Increase (decrease) in accounts payable, accrued expenses and related party payable

 

 

14

 

 

 

(36

)

 

Increase (decrease) in employee-related accrued expenses and long-term benefits

 

 

(5

)

 

 

—

 

 

Increase (decrease) in other current liabilities

 

 

18

 

 

 

(5

)

 

Increase (decrease) in other long-term liabilities

 

 

2

 

 

 

2

 

 

Net cash provided by operating activities

 

 

75

 

 

 

109

 

 

CASH FLOWS FROM INVESTING ACTIVITIES

 

 

 

 

 

Purchase of property and equipment

 

 

(30

)

 

 

(14

)

 

Purchases of debt and equity investments

 

 

(125

)

 

 

(25

)

 

Maturities and sales of debt and equity investments

 

 

47

 

 

 

14

 

 

Cash paid for acquisition of Mentee Robotics, net of cash acquired

 

 

(591

)

 

 

—

 

 

Net cash used in investing activities

 

 

(699

)

 

 

(25

)

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

 

Share-based compensation recharge

 

*

 

 

3

 

 

Net cash provided by financing activities

 

 

—

 

 

 

3

 

 

Effect of foreign exchange rate changes on cash and cash equivalents

 

 

2

 

 

 

2

 

 

Increase (decrease) in cash, cash equivalents and restricted cash

 

 

(622

)

 

 

89

 

 

Balance of cash, cash equivalents and restricted cash, at beginning of year

 

 

1,860

 

 

 

1,438

 

 

Balance of cash, cash equivalents and restricted cash, at end of period

 

$

1,238

 

 

$

1,527

 

 
 

* Less than $1 million.

Mobileye Global Inc.

Reconciliation of GAAP Gross Profit and Margin to Non-GAAP Adjusted Gross Profit and Margin1 (unaudited)

 

Three Months Ended

U.S. dollars in millions

March 28, 2026

 

March 29, 2025

 

Amount

 

% of Revenue

 

Amount

 

% of Revenue

Gross Profit and Margin

$

275

 

49

%

 

$

207

 

47

%

Add: Amortization of acquired intangible assets

 

95

 

17

%

 

 

94

 

21

%

Add: Share-based compensation expense

 

—

 

—

%

 

 

—

 

—

%

Adjusted Gross Profit and Margin

$

370

 

66

%

 

$

301

 

69

%
 

1Adjusted gross margin is calculated as adjusted gross profit as a percentage of revenue

Mobileye Global Inc.

Reconciliation of GAAP Operating Income and Margin to Non-GAAP Adjusted Operating Income and Margin2 (unaudited)

 

Three Months Ended

U.S. dollars in millions

March 28, 2026

 

March 29, 2025

 

Amount

 

% of Revenue

 

Amount

 

% of Revenue

Operating Income (Loss) and Margin

$

(3,896

)

 

(698

)%

 

$

(117

)

 

(27

)%

Add: Amortization of acquired intangible assets

 

113

 

 

20

%

 

 

111

 

 

25

%

Add: Share-based compensation expense

 

84

 

 

15

%

 

 

65

 

 

15

%

Add: Acquisition related expenses

 

6

 

 

1

%

 

 

—

 

 

—

%

Add: Goodwill impairment

 

3,788

 

 

679

%

 

 

—

 

 

—

%

Adjusted Operating Income (Loss) and Margin

$

95

 

 

17

%

 

$

59

 

 

13

%
 

2Adjusted operating margin is calculated as adjusted operating income (loss) as a percentage of revenue

Mobileye Global Inc.

Reconciliation of GAAP Net Income to Non-GAAP Adjusted Net Income (unaudited)

 

Three Months Ended

U.S. dollars in millions

March 28, 2026

 

March 29, 2025

 

Amount

 

% of Revenue

 

Amount

 

% of Revenue

Net Income (Loss)

$

(3,818

)

 

(684

)%

 

$

(102

)

 

(23

)%

Add: Amortization of acquired intangible assets

 

113

 

 

20

%

 

 

111

 

 

25

%

Add: Share-based compensation expense

 

84

 

 

15

%

 

 

65

 

 

15

%

Add: Acquisition related expenses

 

6

 

 

1

%

 

 

—

 

 

—

%

Add: Goodwill impairment

 

3,788

 

 

679

%

 

 

—

 

 

—

%

Less: Income tax effects

 

(77

)

 

(14

)%

 

 

(11

)

 

(3

)%

Adjusted Net Income (Loss)

$

96

 

 

17

%

 

$

63

 

 

14

%

Supplemental Information – Average System Price (unaudited)3

 

Q1 2025

 

Q2 2025

 

Q3 2025

 

Q4 2025

 

Q1 2026

EyeQ and SuperVision revenue (U.S. dollars in millions)

$

415

 

$

481

 

$

478

 

$

420

 

$

535

Number of systems shipped (in millions)

 

8.5

 

 

9.7

 

 

9.2

 

 

8.3

 

 

10.8

Average system price (U.S. dollars)

$

49.0

 

$

49.7

 

$

51.7

 

$

50.8

 

$

49.3
 

3 Average System Price is calculated as the sum of revenue related to EyeQ™ and SuperVision systems, divided by the number of systems shipped.

 

Dan Galves

Investor Relations

[email protected]

Justin Hyde

Media Relations

[email protected]

KEYWORDS: United States North America Israel Middle East

INDUSTRY KEYWORDS: Other Energy Automotive Manufacturing Technology Manufacturing Other Technology Alternative Energy Energy

MEDIA:

Logo
Logo
Posted on

Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

— Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 —

— Positive Interactions with U.S. Food and Drug Administration (FDA) on Design of Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease (FSCD) —

— On Track to Initiate Phase 2b Study in FSCD with Ontunisertib and Phase 2 Study in Idiopathic Pulmonary Fibrosis (IPF) with AGMB-447 in Second Half of 2026 —

— Topline Data from Open-Label Long-term Extension Study (OLE) Part of STENOVA Study with Ontunisertib in FSCD and from Phase 1b IPF Study Cohort with AGMB-447 Expected in Second Half of 2026 —

Antwerp, Belgium, April 23, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today reported financial results for the full year period ended December 31, 2025, and confirmed its outlook for 2026.

“2025 was a pivotal year for Agomab, with significant progress across our clinical programs and the positive topline results of the STENOVA Phase 2a study with ontunisertib in FSCD. Our momentum has continued into 2026 with positive Phase 1 results for AGMB-447 in healthy participants and the successful completion of our IPO,” said Tim Knotnerus, Chief Executive Officer of Agomab. “In the second half of this year, we expect the full read-out of the OLE study with ontunisertib in FSCD as well as the topline IPF cohort data of the Phase 1b study with AGMB-447. Based on the positive regulatory interactions on trial design, we are on track to start both the Phase 2b study with ontunisertib in FSCD and Phase 2 study with AGMB-447 in IPF later this year.”

Pierre Kemula, Chief Financial Officer of Agomab, added, “Thanks to the $208 million in gross proceeds raised from our IPO in February 2026, we are well-capitalized and we expect our cash reserves to last into the first half of 2029. With major milestones approaching later this year, we remain laser-focused on delivering on our corporate and clinical strategy.”

Recent Program Highlights and 2026 Anticipated Milestones 

  • Ontunisertib (AGMB-129), a gut-restricted
    small molecule inhibitor of ALK5
    for the treatment of FSCD 
    • We continue to have positive interactions with the FDA to align on the study design of the Phase 2b study with ontunisertib in FSCD and are on track to initiate the study in the second half of 2026.
    • We are progressing the OLE part of the STENOVA study (Part B) with ontunisertib in FSCD patients, with topline results expected in the second half of 2026. The 48-week data may provide important insights into extended treatment with ontunisertib in FSCD patients.
    • As of February 2026, the Data Safety and Monitoring Board has not raised any safety issue and has recommended for the OLE study to continue as per the protocol with 200mg BID ontunisertib for up to 60 weeks.
    • The results of the 12-week placebo-controlled double-blind part of the STENOVA Phase 2a study with ontunisertib in FSCD (Part A) were presented as a late-breaker at the 21st Congress of ECCO (ECCO’26) in Stockholm, Sweden in February 2026. The late-breaking presentation was also featured by Nature Reviews Gastroenterology & Hepatology as one of the highlights of ECCO’26.
  • AGMB-447, an inhaled small molecule inhibitor of ALK5 in development for the treatment of IPF
    • We continue to enroll participants in the IPF cohort of the Phase 1b study with AGMB-447. In this cohort, up to 12 participants with IPF will receive multiple doses of AGMB-447 or placebo over 14 days. We have dosed the first participants, and expect to report topline results in the second half of 2026.
    • We received positive scientific advice from the UK Medicines and Healthcare products Regulatory Agency (MHRA), supporting our planned Phase 2 trial in IPF patients. We are on track to initiate a Phase 2 proof-of-concept study with AGMB-447 in IPF in the second half of 2026.
    • We were granted a patent covering the composition of matter of AGMB-447 by the United States Patent and Trademark Office (USPTO), solidifying the foundational IP for AGMB-447 in the U.S.

Full Year 2025 Financial Results (consolidated)

  • Cash Position: Cash, cash equivalents and short-term cash investments totaled €116.5 million as of December 31, 2025. Subsequently, in February 2026, we completed our IPO, in which we raised gross proceeds of approximately $208 million, including the proceeds from the underwriters’ partial exercise of their overallotment option, before deducting underwriting discounts and commissions and other offering expenses. We expect that our existing cash and cash investments, including the net proceeds from our IPO, will enable us to fund our operating expenses and capital expenditure requirements into the first half of 2029.
  • R&D Expenses: Research and development (R&D) expenses were €48.9 million for the year ended December 31, 2025, as compared with €39.3 million for the year ended December 31, 2024. The increase in R&D expenses of €9.6 million for the year was primarily due to increased clinical trial expenses, which are outsourced activities, specifically for the two lead programs ontunisertib and AGMB-447.
  • G&A Expenses: General and administrative (G&A) expenses were €12.8 million for the year ended December 31, 2025, as compared with €10.1 million for the year ended December 31, 2024. The increase of €2.7 million for the year mainly relates to increased employee benefits, reflecting organizational scaling to support company growth, including stock-based compensation.
  • Net Loss: Net loss was €62.5 million for the full year ended December 31, 2025, compared to €46.3 million for the full year ended December 31, 2024.

Corporate

  • The company has filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC). The Annual Report is available on the Agomab website at https://agomab.com/ and on the SEC’s website at www.sec.gov.
  • The company will hold its Annual General Meeting (AGM) at 4:00pm CEST on May 26, 2026. The convening notice for the AGM as well as all documents relevant for the meeting are available via the Agomab website at https://ir.agomab.com/governance/shareholder-meetings. 
 
 

Financial performance

Consolidated statement of profit and loss

                   
      For the year ended December 31
(in thousands of €), except per share data           2025      2024      2023
Research and development expenses      (48,877)    (39,310)    (26,311)
General and administrative expenses      (12,791)    (10,133)    (6,097)
Total operating expenses      (61,668)    (49,443)    (32,408)
               
Other operating income      2,393    1,422    1,218
Operating loss      (59,275)    (48,021)    (31,190)
               
Changes in fair value of financial liabilities      (4,857)    848    18,964
Financial expenses      (133)    (357)    (86)
Financial income      1,718    1,267    303
Loss before taxes      (62,547)    (46,263)    (12,009)
               
Income tax (expense)/income      —    (4)    619
Loss for the year      (62,547)    (46,267)    (11,390)
               —
Weighted average number of common shares outstanding      541,126    541,126    541,126
Basic and diluted loss per share (in €)      (143.22)    (107.09)    (35.63)


 

 

 

    For the year ended December 31
(in thousands of €)           2025      2024      2023
Loss for the year      (62,547)    (46,267)    (11,390)
Items that may be reclassified to profit or loss              
Foreign currency translation differences      21    (10)    —
Items that will not be reclassified to profit or loss              
Remeasurement of post-employment benefit obligations      (8)    (73)    —
Other comprehensive income or loss for the year, net of tax      13    (83)    —
Total comprehensive income or loss for the year      (62,534)    (46,350)    (11,390)
 
 
 

Consolidated statement of financial position

      For the year ended per  
       December 31  
(In thousands of €)           2025      2024  
Assets             
Non-current assets             
Intangible assets      20,110    20,110  
Goodwill      8,612    8,612  
Property, plant and equipment      503    619  
Right-of-use assets      1,083    1,373  
Other financial assets      11    12  
Other non-current assets      2,150    1,787  
Total non-current assets      32,469    32,513  
             
Current assets             
Other current assets      4,723    2,386  
Current financial investments      30,096    —  
Cash and cash equivalents      86,418    171,459  
Total current assets      121,237    173,845  
Total assets      153,706    206,358  
             
Equity             
Share capital      223,072    223,072  
Share premium reserve      76,634    76,634  
Retained earnings      (181,714)    (119,181)  
Share-based payment reserves      13,877    8,522  
Other reserves      (967)    (966)  
Equity attributable to the owners of the parent      130,902    188,081  
Total equity      130,902    188,081  
             
Liabilities             
Non-current liabilities             
Non-current lease liabilities      1,005    1,272  
Non-current contingent consideration      3,210    7,879  
Total non-current liabilities      4,215    9,151  
             
Current liabilities             
Current lease liabilities      249    273  
Anti-dilutive warrants      —    —  
Current contingent consideration      6,526    —  
Trade and other payables      10,266    8,052  
Deferred income and accrued charges      1,548    801  
Total current liabilities      18,589    9,126  
Total liabilities      22,804    18,277  
             
Total equity and liabilities      153,706    206,358  
                 
                 
                 

Consolidated statement of cash flows

    For the years ended per December 31
(In thousands of €)      2025      2024      2023
Net loss for the year    (62,547)    (46,267)    (11,390)
Adjustments for non-cash items:              
             
Current income tax expense (income)    —    4    3
Deferred income tax expense (income)    —    —    (622)
Fair value (gain) loss on financial assets    (96)    —    —
Fair value (gain) loss on financial liabilities    4,857    (848)    (18,964)
Depreciation & amortization    219    311    99
Share-based payment expenses    5,355    1,071    2,159
Net foreign exchange losses (gains)    57    231    —
Interest expense    69    77    86
Interest income    (1,614)    (1,218)    (303)
Operating cash flows before movements in working capital    (53,700)    (46,640)    (28,932)
             
movements in working capital:              
             
Decrease/(increase) in other current assets    (2,337)    (315)    1,343
Decrease/(increase) in other non-current assets    (363)    (342)    (331)
Increase/(decrease) in trade and other payables    2,359    (230)    3,686
Increase/(decrease) in deferred income    747    (395)    (580)
             
Income taxes paid    —    (4)    (3)
Interest paid    (69)    (10)    (20)
Interest received    1,622    1,106    245
Net cash flow from /(used in) operating activities    (51,741)    (46,828)    (24,592)
             
Purchases of property, plant and equipment    (4)    (675)    —
Purchase of financial investments    (30,000)    —    40,000
Payment of contingent consideration from previous acquisition    (3,000)    —    —
Net cash flow from /(used in) investing activities    (33,004)    (675)    40,000
             
Repayment of lease liabilities    (338)    (163)    (100)
Proceeds from capital increase    —    97,055    79,871
Share issue costs    —    (129)    (453)
Other financial expense, net    —    —    6
Net cash flow from /(used in) financing activities    (338)    96,762    79,324
             
Net increase/(decrease) in cash and cash equivalents    (85,083)    49,260    94,732
             
Cash and cash equivalents at beginning of year    171,459    122,402    27,670
Effect of foreign exchange rate changes    45    (204)    —
Cash and cash equivalents at end of year    86,418    171,459    122,402
 
 
 

Ontunisertib and AGMB-447 are investigational drugs and not approved by any regulatory authority. Their efficacy and safety have not been established.  

About Agomab

Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. Agomab’s product candidates are designed to target established potent pathways and utilize organ-restricted approaches, with the aim of increasing efficacy while minimizing safety liabilities. Fostering a culture of excellence, Agomab’s mission is to pioneer therapeutics that aim to resolve fibro-inflammation and restore organ function to enable people with these disorders to live fuller and healthier lives.

Cautionary Note Regarding Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding our expected cash runway, including that we anticipate our cash and cash investments and IPO proceeds will extend our runway into the first half of 2029, our focus on the discovery and development of our pipeline of novel product candidates for fibro-inflammatory disorders, the design of planned Phase 2 clinical trials with ontunisertib for FSCD and AGMB-447 for IPF, our expectation to initiate our Phase 2b Study of ontunisertib in FSCD and our Phase 2 study of AGMB-447 in IPF in the second half of 2026, as well as statements regarding future data readouts, including our expectation to release topline data from the OLE part of the STENOVA study and of the Phase 1b IPF Study Cohort with AGMB-447 in the second half of 2026. Forward-looking statements are based on Agomab’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the results of our clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements for product candidates; the impact of governmental laws and regulations on our business; disruptions caused by our reliance on third party suppliers and service providers; the risk that our expectations and management’s guidance regarding our cash position and other financial estimates may be incorrect; and risks related to geopolitical conflicts and macro-economic events. These and other risks and uncertainties are described more fully in our filings and reports with the SEC, including in our most recent annual report on Form 20‐F filed with the SEC and our subsequent filings and reports filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Agomab undertakes no duty to update such information except as required under applicable law. Readers should not rely upon the information in this announcement as current or accurate after its publication date.

Contacts

Investors

Sofie Van Gijsel
VP of Investor Relations
E-Mail: [email protected]
Phone: +1 781 296 1143

Media

Gretchen Schweitzer
Trophic Communications
E-Mail: [email protected] 
Phone: +49 172 861 8540



Posted on

Kuehn Law Encourages Investors of Marqeta, Inc. to Contact Law Firm

NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Marqeta, Inc. (NASDAQ: MQ) breached their fiduciary duties to shareholders.

According to a federal securities lawsuit, Insiders at Marqeta caused the company to misrepresent or fail to disclose that: (1) Marqeta understated the regulatory challenges affecting its business outlook; (2) as a result, Marqeta would have to cut its guidance for the fourth quarter of 2024; and (3) as a result, public statements were materially false and/or misleading at relevant times.

If you currently own MQ and purchased prior to February 28, 2024 please contact Justin Kuehn, Esq. by email at [email protected] or call (833) 672-0814.  Kuehn Law pays all case costs and does not charge its investor clients.Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™  

For additional information, please visit Shareholder Derivative Litigation – Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
[email protected]
(833) 672-0814



Posted on

Sensus Healthcare to Report First Quarter 2026 Financial Results and Hold Business Update Conference Call on May 7, 2026

Sensus Healthcare to Report First Quarter 2026 Financial Results and Hold Business Update Conference Call on May 7, 2026

BOCA RATON, Fla.–(BUSINESS WIRE)–
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the first quarter of 2026 on Thursday, May 7, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions.

Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to pre-register can access the conference call by dialing 844-481-2811 (U.S. and Canada Toll Free) or 412-317-0676 (International). Please ask the operator to be connected to the Sensus Healthcare conference call.

The call will be webcast live and can be accessed at this link or in the Investor Relations section of the Company’s website at www.sensushealthcare.com.

About Sensus Healthcare

Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.

Investor Relations Contact

Leigh Salvo

New Street Investor Relations

[email protected]

KEYWORDS: Florida United States North America

INDUSTRY KEYWORDS: General Health Medical Devices Health Radiology Oncology

MEDIA: